Market News

Jazz Pharmaceuticals (JAZZ) “Buy” Rating Reaffirmed at Cantor Fitzgerald; With $200.0 Target; MARICANN GROUP ORD (MRRCF) SI Increased By 198.04%

MARICANN GROUP ORD (OTCMKTS:MRRCF) had an increase of 198.04% in short interest. MRRCF’s SI was 15,200 shares in December as released by FINRA. Its up 198.04% from 5,100 shares previously. With 44,700 avg volume, 0 days are for MARICANN GROUP ORD (OTCMKTS:MRRCF)’s short sellers to cover MRRCF’s short positions. The stock increased 2.71% or $0.05 during the last trading session, reaching $1.82. About shares traded. Maricann Group Inc. (OTCMKTS:MRRCF) has 0.00% since December 4, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $180.29’s average target is 30.47% above currents $138.19 stock price. Jazz Pharmaceuticals had 63 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Hold” rating by Mizuho on Friday, October 13. The company was maintained on Monday, July 17 by Deutsche Bank. Piper Jaffray maintained the shares of JAZZ in report on Tuesday, August 8 with “Buy” rating. As per Wednesday, June 7, the company rating was maintained by BMO Capital Markets. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has “Buy” rating given on Tuesday, June 27 by Cantor Fitzgerald. As per Monday, April 25, the company rating was upgraded by SunTrust. Wells Fargo maintained the stock with “Buy” rating in Wednesday, November 8 report. Mizuho downgraded Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) rating on Tuesday, November 10. Mizuho has “Neutral” rating and $140 target. H.C. Wainwright initiated Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Friday, August 25 with “Hold” rating. The stock has “Buy” rating by Mizuho on Tuesday, February 21.

Maricann Group Inc. produces and distributes marijuana for medical purposes. The company has market cap of $133.20 million. The firm offers dried marijuana, cannabis oil, and gums. It currently has negative earnings. It also provides accessories, including vaporizers, grinders, and other paraphernalia.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $8.29 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 21.29 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Investors sentiment increased to 1.39 in 2017 Q2. Its up 0.44, from 0.95 in 2017Q1. It is positive, as 31 investors sold Jazz Pharmaceuticals Public Limited Company shares while 79 reduced holdings. 51 funds opened positions while 102 raised stakes. 51.74 million shares or 0.45% less from 51.98 million shares in 2017Q1 were reported. Balyasny Asset Ltd Limited Liability Company holds 0.17% or 270,602 shares. Brighton Jones Ltd Co invested 0.03% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Strs Ohio accumulated 235,800 shares or 0.16% of the stock. Raymond James Associates reported 28,652 shares stake. 1.38M were reported by Bancorp Of New York Mellon. 8,154 are held by Credit Agricole S A. Hsbc Public Ltd accumulated 6,817 shares or 0% of the stock. Panagora Asset Mgmt invested 0% of its portfolio in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Citigroup Inc reported 17,188 shares or 0% of all its holdings. North Star Invest Mngmt Corporation invested in 100 shares. Alphamark Advsr Limited Liability Company has 0% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) for 34 shares. Fmr Limited Liability Corp has 8.29 million shares. Asset Mngmt Inc stated it has 0.01% of its portfolio in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Lpl Fincl Ltd Llc invested 0% of its portfolio in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Stevens Capital L P has invested 0.02% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ).

Since June 15, 2017, it had 0 buys, and 1 sale for $30,130 activity. $30,130 worth of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) shares were sold by MILLER MICHAEL PATRICK.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *